Genetic@
7 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Dorian Manzano
Scoop.it!

After The Biotech Sell-off, How Will Investors Treat Alexion Pharmaceuticals?

After The Biotech Sell-off, How Will Investors Treat Alexion Pharmaceuticals? | Genetic@ | Scoop.it
Actualmente cuenta con un único fármaco aprobado por la FDA, Soliris, que se utiliza para el tratamiento de dos tipos de trastornos de la sangre poco comunes
more...
No comment yet.
Scooped by Dorian Manzano
Scoop.it!

Moderna: Messenger RNA Therapeutics™ - YouTube

Moderna Terapéutica es pionera en productos terapéuticos de ARN mensajero ™, una nueva modalidad en vivo droga que produce proteínas humanas o anticuerpos dentro patie ...
Dorian Manzano's insight:

Moderna :)

more...
No comment yet.
Rescooped by Dorian Manzano from Biodefense News
Scoop.it!

Alexion, Moderna to Develop Rare Disease-Fighting mRNA Therapeutics - Genetic Engineering News

Alexion, Moderna to Develop Rare Disease-Fighting mRNA Therapeutics - Genetic Engineering News | Genetic@ | Scoop.it
Alexion, Moderna to Develop Rare Disease-Fighting mRNA Therapeutics Genetic Engineering News DARPA also took an interest in the platform back in October, awarding Moderna up to $25 million to research and develop the platform as a way to make...

Via Biodefense News
Dorian Manzano's insight:

Coñe bien (Y)

more...
No comment yet.
Scooped by Dorian Manzano
Scoop.it!

Alexion, Moderna announce agreement to develop messenger RNA therapeutics - Boston.com

Alexion, Moderna announce agreement to develop messenger RNA therapeutics - Boston.com | Genetic@ | Scoop.it
Alexion Pharmaceuticals Inc. and Moderna Therapeutics announced an exclusive strategic agreement Monday for the discovery and development of messenger RNA Therapeutics to treat rare diseases. Under the agreement, Alexion will make an upfront payment to Cambridge-based Moderna of $100 million to purchase 10 product options to develop and commercialize treatments for rare diseases with Moderna’s mRNA Therapeutics platform, the two companies said in a press release. In addition, Connecticut-based Alexion has made a $25 million preferred equity investment into Moderna. Messenger RNA therapeutics is a new drug modality that produces human proteins or antibodies inside patient cells. This platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions.
Dorian Manzano's insight:

Alexion 

more...
No comment yet.
Scooped by Dorian Manzano
Scoop.it!

Alexion Pharmaceuticals and Moderna Therapeutics Announce Exclusive Strategic Agreement to Develop Messenger RNA Therapeutics™ for Rare Diseases | Business Wire

Alexion Pharmaceuticals and Moderna Therapeutics Announce Exclusive Strategic Agreement to Develop Messenger RNA Therapeutics™ for Rare Diseases | Business Wire | Genetic@ | Scoop.it
Alexion Pharmaceuticals, Inc. (ALXN) y Moderna Terapéutica anunciaron hoy un acuerdo estratégico exclusivo para el descubrimiento y desarrollo de mí
Dorian Manzano's insight:

Alexion y Moderna 

 

more...
No comment yet.